Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
November 6, 2024 4:05 PM EST 14% year-over-year revenue increase from combined key growth drivers:
Xywav®, Epidiolex® and Rylaze®
2024 total revenue guidance affirmed at $4.0 to $4.1 billion
Zanidatamab 2L BTC PDUFA date of November 29, 2024
Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25
DUBLIN, Nov. 6, 2024 Â /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and... More
